GlassScriptPhysician profile
Sharique A Ansari
NPI 1891944617
$195,161.16
in general payments reported to CMS, 2019-2025
87 companies · $119K in 2025
The $119K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,398 · 2020: $5,382 · 2021: $6,578 · 2022: $11K · 2023: $7,982 · 2024: $41K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Travel and Lodging: $16K · Food and Beverage: $16K · Consulting Fee: $6,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,580.00 |
| Travel and Lodging | $16,218.68 |
| Food and Beverage | $15,972.32 |
| Consulting Fee | $6,705.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $50,460.55 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Janssen Biotech, INC. | $43,036.83 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $35,837.40 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $22,909.20 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $17,973.10 | 2019-2025 | Uplizna, Bkemv |
| Abbvie INC. | $3,532.10 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Akcea Therapeutics, INC. | $2,105.81 | 2019-2020 | |
| Csl Behring | $1,806.47 | 2019-2024 | Hizentra |
| Biogen, INC. | $1,485.93 | 2019-2025 | Tysabri, Leqembi, Vumerity |
| Teva Pharmaceuticals USA, INC. | $1,325.26 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $1,041.42 | 2020-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,037.05 | 2019-2024 | |
| Allergan, INC. | $920.32 | 2019-2022 | |
| Grifols USA, LLC | $886.09 | 2019-2025 | Gamunex-C |
| Genentech USA, INC. | $657.48 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
Show all 87 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharique Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.